Skip to main content
SpringerLink
Log in

Carvedilol for Heart Failure: Clinical Trials in Progress

  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cleland JGF, Bristow MR, Erdmann E, et al. Beta-blocking agents in heart failure. Should they be used and how? Eur Heart J 1996;17:1629–1639.

    Google Scholar 

  2. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel J. Clinical effects of b-adrenergic blockade in chronic heart failure. A meta-analysis of double-blind placebo-controlled, randomised trials. Circulation 1998;98:1184–1191.

    Google Scholar 

  3. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441–1446.

    Google Scholar 

  4. The Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. 3-year follow-up of patients randomised in the metoprolol in dilated cardiomyopathy trial. Lancet 1998;351:1180–1181.

    Google Scholar 

  5. CIBIS Investigators and Committees. A randomized trial of b-blockade in heart failure: The cardiac insufficiency bisoprolol study. Circulation 1994;90:1765–1773.

    Google Scholar 

  6. Packer M, Bristow MR, Cohn JN, et al, for the US Carvedilol Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349–1355.

    Google Scholar 

  7. Packer M, Colucci WS, Sackner-Bernstein JD, et al., for the PRECISE Study Group. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Circulation 1996;94:2793–2799.

    Google Scholar 

  8. Bristow MR, Gilbert EM, Abraham WT, et al., for the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in patients with chronic heart failure. Circulation 1996;94: 2807–816.

    Google Scholar 

  9. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomized trial. Lancet 1999;353:9–13.

    Google Scholar 

  10. Goldstein S. Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF): An update after completed randomisation. The International Steering Committee on behalf of the MERIT-HF Study Group. Presented at the 71st Scientific Sessions of the American Heart Association, Dallas, 8–11 November 1998.

  11. Cleland JGF, Freemantle N, McGowan J, Clark A. The evidence for beta-blockers equals or surpasses that for ACE inhibitors in heart failure. BMJ 1999:in press.

  12. Yoshikawa T, Port JD, Asano K, et al. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J 1996;17(Suppl B):8–16.

    Google Scholar 

  13. Yue T-L, Cheng HY, Lysko PG et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992;263:92–98.

    Google Scholar 

  14. Di Lenarda A, Gilbert EM, Olsen SL, Mealey PC, Bristow MR. Acute hemodynamic effects of carvedilol versus metoprolol in idiopathic dilated cardiomyopathy (Abstract). J Am Coll Cardiol1991;17:142A.

    Google Scholar 

  15. Metra M, Nardi M, Giubbini R, DeiCas L. Effects of short and long-term carvedilol administration on rest an exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994;24:1678–1687.

    Google Scholar 

  16. Ohlstein EH, Douglas SA, Sung C-P et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci USA 1993;90:6189–6193.

    Google Scholar 

  17. Eichhorn EJ. Effects of bucindolol in heart failure. Am J Cardiol 1993;71:1C–6C.

    Google Scholar 

  18. Rimele TJ, Aahus LL, Lorenz RR, Rooke TW, Vanhoutte PM. Pharmacology of bucindolol in isolated canine vascular smooth muscle. J Pharmcol Exp Ther 1984;231:317–325.

    Google Scholar 

  19. Schliep H-J, Harting J. Beta1 selectivity of bisoprolol, a new b-adrenoceptor antagonist, in anesthetized dogs and guinea pigs. J Cardiovasc Pharmacol 1984;6:1156–1160.

    Google Scholar 

  20. Poole-Wilson P, Swedberg K, Remme WJ, et al. A multicentre randomised double-blind study to compare the effect on mortality and morbidity over 24–44 months of carvedilol and metoprolol in patients with moderate or severecongestive heart failure (NYHA II-IV)—COMET. In: European Society of Cardiology, ed.: Heart Failure '97 Meeting, Cologne, 1997; p41, Abstract P155.

  21. Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. Double-blind placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995;92:1499–1506.

    Google Scholar 

  22. Cohn JN, Fowler MB, Bristow MA, et al. Safety and efficacy of carvedilol in severe chronic heart failure. J Cardiac Failure 1997;3:173–179.

    Google Scholar 

  23. CIBIS II Scientific Committee. Design of the cardiac insufficiency bisoprolol study II. Fundam Clin Pharmacol 1997;11:138–142.

    Google Scholar 

  24. Packer M, Fowler M, Rouleau J, et al., for the COPERNICUS Investigators. COPERNICUS (Carvedilol Prospective Randomized Cumulative Survival Trial). A multicenter randomized double-blind, placebo-controlled study to determine the effect of carvedilol on mortality over 6–45 months in patients with severe congestive heart failure. In: European Society of Cardiology, ed.: Heart Failure '97 Meeting, Cologne, 1997;42, Abstract P158.

  25. Basu S, Senior R, Raval U, Dore C, Lahiri A. Carvedilol reduces cardiac events in patients with post-infar ction myocardial ischaemia detected by T1-201 imaging. J Am Coll Cardiol1996;27(2 Suppl A):353A.

    Google Scholar 

  26. Basu S, Senior R, Raval U, van der Does R, Bruckner T, Lahiri A. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction: A placebo controlled, randomized trial. Circulation 1997;96:183–91.

    Google Scholar 

  27. Dargie HJ, Colucci WS, Ford I, Lopez-Sendon J-L, Remme WJ, Sharpe N, on behalf of the CAPRICORN study group. CAPRICORN—A study of carvedilol post myocardial infarction. In: European Society of Cardiology, ed.:Heart Failure '97 Meeting, Cologne, 1997;42, Abstract P157.

  28. Cleland JGF, McGowan J, Cowburn PJ. b-blockers for chronic heart failure: From prejudice to enlightenment. J Cardiovasc Pharmacol 1998;32(Suppl 1):S52–S60.

    Google Scholar 

  29. Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986;73:503–510.

    Google Scholar 

  30. Cleland JGF, Swedberg K, Poole-Wilson PA. Successes and failures of current treatment of heart failure. Lancer 1998; 352(Suppl I):SI19–SI28.

    Google Scholar 

  31. Pfeffer MA, Greaves SC, Arnold J M, et al. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation 1997;95:2643–2651.

    Google Scholar 

  32. Josephson ME, NisamS. The AVID trial: Evidence based on randomized control trials— Is the AVID study too late? Am J Cardiol 1997;80:194–197.

    Google Scholar 

  33. Fogoros RN. Why the antiarrhythmics versus implantable defibrilliator (AVID) trial sets the wrong precedent. Am J Cardiol 1997;80:762–765.

    Google Scholar 

  34. Cleland JGF, McGowan J. Heart failure due to ischaemic heart disease: Epidemiology, pathophysiology and progression J Cardiovasc Pharmacol 1999:in press. 1999.

  35. Bristow MR, Gilbert EM, Abraham WT, Adams KT, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N, for the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807–2816

    Google Scholar 

  36. Woodley SL, Gilbert EM, Anderson JL, O'Connell JB, Deitchman D, Yanowitz FG, Mealey PC, et al. B-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991;84: 2426–2441.

    Google Scholar 

  37. Bristow MR, O'Connell JB, Gilbert EM, et al. Dose-response of chronic B-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation 1994;89:1632–1642.

    Google Scholar 

  38. Fisher ML, Gottlieb SS, Plotnick G, Greenberg NL, Patten RD, Bennett SK, et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: A randomized trial. J Am Coll Cardiol1994;23:943–950.

    Google Scholar 

  39. Dilsizian V, Bonow RO. Current diagnostic techniques of assessing myocardial viability in patients with hibernating and stunned myocardium. Circulation 1993;87:1–20.

    Google Scholar 

  40. Rahimtoola SH. Importance of diagnosing hibernating myocardium: How and in whom? JACC 1997;30:1701–1706.

    Google Scholar 

  41. Vanoverschelde JJ, Wijns W, Depre C, Essamri B, Heyndrickx GR, Borgers M, Bol A, Melin JA. Mechanisms of chronic regional postischemic dysfunction in humans: New insights from the study of noninfarcted collateral-dependent myocardium. Circulation 1993;87:1513–1523.

    Google Scholar 

  42. Paolisso G, Gambardella A, Marasso G, et al. Metabolic and cardiovascular benefits deriving from B-adrenergic blockade in chronic congestive heart failure. Am Heart J 1992; 123:103–110.

    Google Scholar 

  43. Feuerstein GZ, Ruffolo RR. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur Heart J 1995;16:38–42.

    Google Scholar 

  44. Yue T, Wang X, Gu JL, Ruffolo RRJ, Feuerstein GZ. Carvedilol, a new vasodilating beta-adrenoceptor blocker, inhibits oxidation of low-density lipoproteins by vascular smooth muscle cells and prevents leukocyte adhesion to smooth muscle cells. J Pharm Exp Therapeutics 1995;273: 1442–1449.

    Google Scholar 

  45. Cleland JGF, Pennell DJ, Murray GD, et al. The Carvedilol Hibernation Reversible Ischaemia Trial;Marker of success (CHRISTMAS). Eur J Heart Failure 1999:1:191–196.

    Google Scholar 

  46. Remme WJ, Harland D, Court M, for the CARMEN Investigators. CARMEN: Carvedilol ACE inhibitor Remodelling Mild heart failure EvaluationN). In: European Society of Cardiology, ed. Heart Failure '97 Meeting, Cologne, 1997;41, Abstract P156.

  47. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335–371.

    Google Scholar 

  48. Bristow MR. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with b-blocking agents. Am J Cardiol 1993;71:12C–22C.

    Google Scholar 

  49. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996;94:2817–2825.

    Google Scholar 

  50. Colucci WS, Packer M, Bristow MR, et al. for the US Carvedilol Heart Failure Study Group. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996;94:2800–2806.

    Google Scholar 

  51. Australia–New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997;349:375–380.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, University of Hull, Kingston-upon-Hull, UK

    James McGowan, Richard Murphy & John G.F. Cleland

Authors
  1. James McGowan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard Murphy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John G.F. Cleland
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

McGowan, J., Murphy, R. & Cleland, J.G. Carvedilol for Heart Failure: Clinical Trials in Progress. Heart Fail Rev 4, 89–96 (1999). https://doi.org/10.1023/A:1009812019524

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1009812019524

Keywords

Search

Navigation